Overview

A 1238-gene solid tumor panel represents the deep end of comprehensive genomic profiling, reading more than a thousand genes to build a near-complete alteration map from one specimen. Its value is population-level: it extends precise biomarker testing to patients whose tumors are rare, atypical, or simply unexplained by standard smaller panels, broadening access to targeted and tissue-agnostic options that might otherwise be missed.

Coverage for Rare and Hybrid Tumors

Standard panels often under-sample the genes that drive uncommon entities, leaving rare tumor populations without a clear target. A panel of this breadth captures alterations across a wide gene set, increasing the odds of finding an actionable driver even in histologies that rarely appear in clinical trials. For molecular tumor boards, that breadth turns a no-target result into a shorter list of genuine possibilities worth pursuing, and supports reclassification of tumors that defy standard histology.

Population-Level Utility in Precision Oncology

Some of the most useful findings are tumor-agnostic. Alterations such as NTRK fusions, high microsatellite instability, or elevated tumor mutational burden can occur across many cancer types and point to therapies approved regardless of site. A broad panel is well placed to surface these tissue-agnostic signals, helping patients in small or under-studied populations reach the same precision-oncology options as those with common cancers, which is where the population benefit is largest.

Cost and Access Considerations

Depth comes with a higher per-test cost and a greater interpretive burden, so the panel is best positioned where smaller assays have already failed to find a target or where the histology itself argues for broad sampling. Buyers should weigh the price per report against the likelihood of changing management, and should confirm that the laboratory can return results fast enough to matter for a patient already in treatment. Reimbursement pathways differ by market and often hinge on documented clinical utility.

Integrating Results into Care Pathways

The depth of a 1238-gene report demands disciplined interpretation. Results are best reviewed in a multidisciplinary molecular tumor board that weighs actionability, evidence level, and trial availability before recommending therapy. For the procurement side, the consideration is whether the laboratory can return a report that distinguishes high-confidence targets from variants of uncertain significance, so clinicians are not buried in data without guidance.

FAQ

Q: Who benefits most from a 1238-gene solid tumor panel? A: Patients with rare or atypical solid tumors, or those whose smaller standard panels returned no clear target, gain the widest chance of finding an actionable alteration.

Q: Can the panel identify tissue-agnostic treatment opportunities? A: Yes. It is positioned to detect tumor-agnostic markers such as NTRK fusions, high microsatellite instability, and elevated tumor mutational burden across cancer types.

Q: How long does a broad profiling report usually take? A: Turnaround depends on the laboratory workflow, but comprehensive profiling of this depth commonly falls within a one-to-three-week window from sample receipt.